All holdings
Bausch Health Companies BHC
Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them
Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance
Share price change by quarter +17.1% Q3 ’24
-1.2% Q4 ’24
-19.7% Q1 ’25
+2.9% Q2 ’25
-3.2% Q3 ’25
+7.8% Q4 ’25
-22.3% Q1 ’26
-8.7% Q2 ’26
Q3 ’24: +17.1%; Q4 ’24: -1.2%; Q1 ’25: -19.7%; Q2 ’25: +2.9%; Q3 ’25: -3.2%; Q4 ’25: +7.8%; Q1 ’26: -22.3%; Q2 ’26: -8.7% Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.
Managers holding it, by quarter 4 Q4 ’23
4 Q1 ’24
3 Q2 ’24
3 Q3 ’24
3 Q4 ’24
3 Q1 ’25
3 Q2 ’25
2 Q3 ’25
2 Q4 ’25
1 Q1 ’26
1 Q2 ’26
0 Q3 ’26
Q4 ’23: 4; Q1 ’24: 4; Q2 ’24: 3; Q3 ’24: 3; Q4 ’24: 3; Q1 ’25: 3; Q2 ’25: 3; Q3 ’25: 2; Q4 ’25: 2; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0 Counts the managers on this site whose 13F for that quarter includes Bausch Health Companies.
Who holds it Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.
Managers holding Bausch Health Companies Manager Portfolio▼ Value Change Held for Biglari Capital 0.0%$202k $202k 32 qtrs
Download the holders: CSV · JSON · Markdown
Directors buying and selling Open-market trades by directors, officers and 10% holders over the last 12 months. How this works From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Sort by Date (high to low) Date (low to high) Who (Z–A) Who (A–Z) Shares (high to low) Shares (low to high) Value (high to low) Value (low to high) Insider purchases and sales of Bausch Health Companies Date▼ Who Bought or sold Shares Price Value Filing 19 Aug 2026 Lenar Aimee J.President, US Pharma ▼ Sold 36,827 $7.03 $259k Form 4
About the company Sector Health care · Pharmaceutical Preparations Incorporated in New Jersey Financial year ends 31 December Shares outstanding 374m at 24 Jul 2026 SEC filings Annual reports and other filings on EDGAR Revenue and profit $5.8bn 2013
$10bn 2015
$8.7bn 2017
$8.6bn 2019
$8.4bn 2021
$8.8bn 2023
$10bn 2025
2013: $5.8bn; 2014: $8.2bn; 2015: $10bn; 2016: $9.7bn; 2017: $8.7bn; 2018: $8.4bn; 2019: $8.6bn; 2020: $8.0bn; 2021: $8.4bn; 2022: $8.1bn; 2023: $8.8bn; 2024: $9.6bn; 2025: $10bn Bausch Health Companies revenue and net income by year Year Revenue Net income 2025 $10bn $157m 2024 $9.6bn −$46.0m 2023 $8.8bn −$592m 2022 $8.1bn −$225m 2021 $8.4bn −$948m 2020 $8.0bn −$560m 2019 $8.6bn −$1.8bn 2018 $8.4bn – 2017 $8.7bn – 2016 $9.7bn – 2015 $10bn – 2014 $8.2bn – 2013 $5.8bn –
From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.